STUDY OF OBLIMERSEN (GENASENSETM, G3139) IN ADVANCED MALIGNANCIES

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall goal of this protocol is to develop a novel therapy for cancer, by combining a cytotoxic chemotherapy combination with a new inhibitor of apoptosis. The rationale for the study is several fold. The cytotoxic agent Gemcitabine has substantial activity against several cancers. Oblimersen is an antisense inhibitor of bcl-2 and has been shown to produce growth inhibition and shrinkage in some human tumors as a single agent.